Cargando…
BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane
BACKGROUND: Haploinsufficiency may contribute to the development of breast cancer among women with a BRCA1 mutation. Thus, interventions that enhance BRCA1 expression may represent avenues for prevention. Studies have shown that 3,3′-diindolylmethane (DIM) can upregulate BRCA1 expression in breast c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183839/ https://www.ncbi.nlm.nih.gov/pubmed/25025957 http://dx.doi.org/10.1038/bjc.2014.391 |
_version_ | 1782337749061206016 |
---|---|
author | Kotsopoulos, J Zhang, S Akbari, M Salmena, L Llacuachaqui, M Zeligs, M Sun, P Narod, S A |
author_facet | Kotsopoulos, J Zhang, S Akbari, M Salmena, L Llacuachaqui, M Zeligs, M Sun, P Narod, S A |
author_sort | Kotsopoulos, J |
collection | PubMed |
description | BACKGROUND: Haploinsufficiency may contribute to the development of breast cancer among women with a BRCA1 mutation. Thus, interventions that enhance BRCA1 expression may represent avenues for prevention. Studies have shown that 3,3′-diindolylmethane (DIM) can upregulate BRCA1 expression in breast cancer cells. This has yet to be demonstrated in vivo. METHODS: We conducted a study to evaluate the ability of oral DIM to upregulate BRCA1 mRNA expression in white blood cells. A total of 18 women were enroled in the study, including 13 BRCA1 mutation carriers who received 300 mg per day of Rx Balance BioResponse DIM for 4–6 weeks (intervention group) and 5 BRCA1 mutation carriers who did not take DIM (control group). BRCA1 mRNA expression was assessed at baseline and at 4–6 weeks by real-time, quantitative PCR and the relative change in BRCA1 mRNA expression (that is, 2(−ΔΔC(T))) was calculated. RESULTS: The relative change in BRCA1 mRNA expression among women in the intervention group achieved borderline significance (P paired t-test=0.05). In the intervention group, BRCA1 mRNA expression increased in 10 of the participants, decreased in 2 and remained unchanged in 1 of the participants following DIM intervention (P sign test=0.02). On average, women in the intervention group experienced a 34% increase in BRCA1 mRNA expression (range −24 to 194%). There was no significant difference in the relative change in BRCA1 mRNA expression among women in the control group (P paired t-test=0.45). CONCLUSIONS: Under the tested conditions, oral DIM was associated with an increase in BRCA1 mRNA expression in women with a BRCA1 mutation. The possibility of mitigating the effect of an inherited deleterious BRCA1 mutation by increasing the physiologic expression of the gene and normalising protein levels represents a clinically important paradigm shift in the prevention strategies available to these high-risk women. Future studies with a larger sample size and higher doses of DIM are warranted. |
format | Online Article Text |
id | pubmed-4183839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-41838392015-09-23 BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane Kotsopoulos, J Zhang, S Akbari, M Salmena, L Llacuachaqui, M Zeligs, M Sun, P Narod, S A Br J Cancer Clinical Study BACKGROUND: Haploinsufficiency may contribute to the development of breast cancer among women with a BRCA1 mutation. Thus, interventions that enhance BRCA1 expression may represent avenues for prevention. Studies have shown that 3,3′-diindolylmethane (DIM) can upregulate BRCA1 expression in breast cancer cells. This has yet to be demonstrated in vivo. METHODS: We conducted a study to evaluate the ability of oral DIM to upregulate BRCA1 mRNA expression in white blood cells. A total of 18 women were enroled in the study, including 13 BRCA1 mutation carriers who received 300 mg per day of Rx Balance BioResponse DIM for 4–6 weeks (intervention group) and 5 BRCA1 mutation carriers who did not take DIM (control group). BRCA1 mRNA expression was assessed at baseline and at 4–6 weeks by real-time, quantitative PCR and the relative change in BRCA1 mRNA expression (that is, 2(−ΔΔC(T))) was calculated. RESULTS: The relative change in BRCA1 mRNA expression among women in the intervention group achieved borderline significance (P paired t-test=0.05). In the intervention group, BRCA1 mRNA expression increased in 10 of the participants, decreased in 2 and remained unchanged in 1 of the participants following DIM intervention (P sign test=0.02). On average, women in the intervention group experienced a 34% increase in BRCA1 mRNA expression (range −24 to 194%). There was no significant difference in the relative change in BRCA1 mRNA expression among women in the control group (P paired t-test=0.45). CONCLUSIONS: Under the tested conditions, oral DIM was associated with an increase in BRCA1 mRNA expression in women with a BRCA1 mutation. The possibility of mitigating the effect of an inherited deleterious BRCA1 mutation by increasing the physiologic expression of the gene and normalising protein levels represents a clinically important paradigm shift in the prevention strategies available to these high-risk women. Future studies with a larger sample size and higher doses of DIM are warranted. Nature Publishing Group 2014-09-23 2014-07-15 /pmc/articles/PMC4183839/ /pubmed/25025957 http://dx.doi.org/10.1038/bjc.2014.391 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Clinical Study Kotsopoulos, J Zhang, S Akbari, M Salmena, L Llacuachaqui, M Zeligs, M Sun, P Narod, S A BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane |
title | BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane |
title_full | BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane |
title_fullStr | BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane |
title_full_unstemmed | BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane |
title_short | BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane |
title_sort | brca1 mrna levels following a 4–6-week intervention with oral 3,3′-diindolylmethane |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183839/ https://www.ncbi.nlm.nih.gov/pubmed/25025957 http://dx.doi.org/10.1038/bjc.2014.391 |
work_keys_str_mv | AT kotsopoulosj brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane AT zhangs brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane AT akbarim brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane AT salmenal brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane AT llacuachaquim brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane AT zeligsm brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane AT sunp brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane AT narodsa brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane |